Despite these clinical observations, there has been no investigation examining the anticancer efficacy of evofosfamide alone or in combination with either the Proapoptotic Receptor Agonists (PARAs) dulanermin (formerly known as Apo2L/TRAIL), or drozitumab for the treatment of osteosarcoma. This evidence concerns the gene TNFSF10 and osteosarcoma.